A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

which is a large patient group that had previously been treated by other drugs that don’t target HER2. Over the past five years, Daiichi Sankyo has paid an average of 55% of net profit in dividends.

Medicine, reads: “St. Martin ... rupturing the lower portion of the left lobe of the lung and lacerating the stomach by a spicule of the rib that was blown through its coat; landing the charge ...

Other approved drugs for patients with advanced gastric or gastroesophageal cancer include AstraZeneca and Daiichi Sankyo's ...

Daiichi Sankyo Co. will seek to maintain its edge over competitors in precision cancer therapies, by pushing ahead with clinical trials of drug candidates being developed using new technology ...

as well as combination studies with other drugs including Celgene's Vidaza (azacitidine) or low dose cytarabine. For Daiichi Sankyo, the acquisition of Ambit is its third bolt-on deal in oncology ...

As one of the leading Japanese pharmaceutical companies with headquarters in Europe, Daiichi Sankyo aims to revolutionize treatment standards. Daiichi Sankyo, a pharmaceutical group boasting over ...

Japan's Daiichi Sankyo applies for approval of mRNA COVID vaccine Approval would give Japan a home-grown mRNA vaccine of the type that has made up the bulk of its COVID inoculations so far.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...